A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. [electronic resource]
Producer: 20180417Description: 2615-2623 p. digitalISSN:- 1029-2403
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bayes Theorem
- Bortezomib -- administration & dosage
- Dexamethasone -- administration & dosage
- Female
- Hematologic Diseases -- chemically induced
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Prospective Studies
- Remission Induction
- Waldenstrom Macroglobulinemia -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.